Parkinson Disease Drug Market Size, Share, Growth, and Industry Analysis, By Type (Decarboxylase Inhibitors, Dopamine Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitor, Catechol-O-Methyltransferase (COMT) Inhibitors, Others), By Application (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Regional Insights and Forecast to 2035

Parkinson Disease Drug Market Overview

The global Parkinson disease drug market size is estimated at USD 8,456.19 million in 2026 and is projected to reach USD 19,124.88 million by 2035, registering a CAGR of 9.49% during the forecast period. Market expansion is driven by increasing Parkinson disease prevalence, growing demand for advanced neurological treatments, and continuous pharmaceutical innovation. Rising adoption of dopamine agonists, extended-release formulations, and targeted drug delivery systems, alongside improving healthcare infrastructure and increasing investment in neurological research, is expected to support sustained market development worldwide.

The United States Parkinson disease drug market demonstrates significant pharmaceutical demand, supported by approximately 1.1 million individuals living with the condition. Nearly 90,000 Americans receive a Parkinson disease diagnosis annually, increasing the population requiring neurological consultation and prescription treatment. The United States maintains established pharmaceutical manufacturing capabilities, specialized neurological research institutions, and extensive hospital pharmacy networks. Increasing utilization of carbidopa-levodopa combinations, dopamine agonists, and advanced infusion therapies influences treatment practices. Insurance coverage, specialist consultations, clinical trials, and regulatory approvals encourage adoption of innovative medications. Growing interest in personalized neurological therapies also supports pharmaceutical development focused on improved motor control, medication convenience, and long-term treatment effectiveness.

Key Findings

• Market Size and Forecast:  The global Parkinson disease drug market is estimated at USD 8,456.19 million in 2026, supported by increasing neurological treatment demand.
• Type Leadership: Decarboxylase inhibitors hold an estimated 49% market share, supported by established carbidopa-levodopa prescribing and effectiveness in managing Parkinson disease motor
• symptoms. Application Leadership: Retail pharmacies account for an estimated 59% market share, driven by repeat prescriptions, outpatient neurological treatment, and established medication distribution networks.
• Key Company Landscape: AbbVie and Acadia Pharmaceuticals maintain prominent neurological treatment portfolios, advancing D1/D5 receptor therapies, continuous dopaminergic delivery, and Parkinson disease psychosis management.
• Leading Region: North America commands an estimated 38% market share, supported by specialist neurological infrastructure, pharmaceutical innovation, prescription coverage, and advanced treatment availability.

Latest Trends

The Parkinson disease drug market is witnessing significant changes through development of advanced drug delivery technologies, differentiated dopamine receptor therapies, and improved pharmaceutical formulations. More than 10 million individuals worldwide are affected by Parkinson disease, creating substantial demand for medications that maintain neurological functioning and improve everyday mobility. Pharmaceutical manufacturers are expanding research into continuous subcutaneous infusion systems that provide consistent medication exposure and reduce unpredictable symptom fluctuations. Selective D1/D5 receptor agonists represent an emerging treatment approach designed to stimulate specific dopamine receptor pathways. Extended-release carbidopa-levodopa formulations are attracting attention because they can improve symptom management between medication administrations. Increasing development of patient-friendly pharmaceutical technologies supports treatment adherence and broader utilization of advanced neurological therapies. Clinical research increasingly examines quality of life, movement stability, and functional independence alongside traditional measurements of medication effectiveness.

Another important Parkinson disease drug market trend involves increasing development of personalized therapies addressing motor complications and nonmotor neurological symptoms. Approximately 80% of patients may experience sleep disturbances during Parkinson disease progression, strengthening interest in comprehensive therapeutic management. Pharmaceutical companies are investigating advanced treatments for hallucinations, dyskinesia, movement difficulties, and fluctuating medication responses. Connected infusion technologies, digital medication reminders, and specialist pharmacy services are supporting more coordinated neurological treatment delivery. Recent clinical findings have demonstrated 3.07 additional hours of daily good on time among a specific group of patients transitioning to an advanced levodopa formulation. Such clinical improvements encourage pharmaceutical investment in extended-release products and optimized treatment combinations. However, adverse medication reactions, reimbursement restrictions, and variable patient responses continue influencing prescription decisions and commercialization strategies.

Market Dynamics

DRIVER

"Increasing prevalence of Parkinson disease and demand for advanced neurological medications."

The increasing prevalence of Parkinson disease represents a major driver of the global Parkinson disease drug market. More than 10 million individuals worldwide live with Parkinson disease, creating sustained demand for long-term pharmaceutical treatment. Approximately 90,000 individuals receive a new diagnosis annually in the United States, further strengthening demand for neurological medications. Progressive deterioration of dopamine-producing neurons frequently requires medication adjustments and combination therapy. Increasing healthcare awareness, improved diagnostic technologies, and expansion of specialist neurological clinics encourage treatment initiation. Pharmaceutical manufacturers are developing improved carbidopa-levodopa formulations, dopamine agonists, and continuous drug delivery systems to address changing patient requirements. Growing recognition of motor and nonmotor complications also supports broader treatment adoption.

RESTRAINT

"Adverse medication effects and limitations associated with prolonged neurological treatment."

The Parkinson disease drug market faces substantial restraints associated with medication-related complications and variable treatment effectiveness. Men are approximately 1.5 times more likely to develop Parkinson disease than women, creating differences in patient demographics and neurological treatment requirements. Approximately 4% of affected individuals receive a diagnosis before age 50, highlighting the need for medication management across different patient groups. Long-term levodopa treatment may produce dyskinesia, motor fluctuations, and changing therapeutic responses. Dopamine agonists can cause hallucinations, excessive sleepiness, and impulse control disturbances. Additional restrictions include treatment affordability, limited specialist access, and complicated dosing schedules. These factors create challenges for pharmaceutical adoption and sustained medication adherence.

OPPORTUNITY

"Expanding development of targeted dopamine therapies and continuous drug delivery systems."

Innovation in advanced neurological therapeutics creates substantial opportunities for companies operating in the Parkinson disease drug market. Selective D1/D5 receptor agonists offer differentiated approaches to dopamine receptor stimulation and motor symptom control. Pharmaceutical research increasingly progresses through 3 major clinical trial phases before regulatory evaluation, creating opportunities for specialized neurological development programs. Continuous subcutaneous infusion technologies are attracting interest because they can maintain medication delivery throughout waking hours. Extended-release oral formulations also offer opportunities to reduce medication burden and improve treatment convenience. Additional pharmaceutical development targets neuroprotective mechanisms, alpha-synuclein pathways, and personalized treatment approaches. Partnerships among biotechnology developers, neurological research institutions, and pharmaceutical manufacturers can accelerate commercialization.

CHALLENGE

"Progressive neurological deterioration and unequal access to innovative Parkinson disease treatments."

Progressive disease characteristics create persistent challenges for pharmaceutical companies and healthcare providers. More than 10 million individuals worldwide require potential access to Parkinson disease care, making medication accessibility a significant global healthcare concern. Existing pharmacological treatments primarily address symptoms rather than reversing neuronal degeneration, creating unmet demand for disease-modifying therapies. Approximately 80% of patients may experience sleep disturbances, further complicating neurological treatment management. Advanced infusion systems require specialized training, medical supervision, and reliable pharmaceutical supply infrastructure. Healthcare disparities restrict access to innovative medicines in developing regions. Clinical trials also face challenges from differences in disease progression, patient responses, and treatment effectiveness. These conditions require continuous pharmaceutical innovation and careful treatment monitoring.

Parkinson Disease Drug Market Segmentation

The Parkinson disease drug market is segmented into 5 therapeutic categories based on medication mechanisms and clinical applications. Distribution analysis evaluates 3 major pharmacy channels, including hospital pharmacies, retail pharmacies, and online pharmacies. Therapeutic segmentation covers decarboxylase inhibitors, dopamine agonists, monoamine oxidase type B inhibitors, catechol-O-methyltransferase inhibitors, and other neurological medications. Prescription selection depends on disease progression, clinical symptoms, medication tolerability, and individual treatment requirements. Retail pharmacies support routine neurological prescriptions, while hospital pharmacies manage complex treatment requirements. Online pharmacies are increasingly important for medication accessibility, refill convenience, and long-term prescription management across established healthcare systems.

The following market-share percentages are analytical estimates, not independently verified industry-wide measurements. The same estimates are maintained throughout the report.

By Type

Based on Type the global market can be categorized in to Decarboxylase Inhibitors, Dopamine Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitor, Catechol-O-Methyltransferase (COMT) Inhibitors, and Others.

• Decarboxylase Inhibitors: Decarboxylase inhibitors represent an estimated 49% of the Parkinson disease drug market, making this the leading therapeutic category within the specified segmentation. Carbidopa is widely combined with levodopa to prevent premature peripheral conversion into dopamine, improving medication availability within the central nervous system. This combination remains fundamental to treatment of bradykinesia, rigidity, and other movement-related symptoms. Extended-release levodopa formulations and continuous infusion therapies have further expanded treatment possibilities. Pharmaceutical manufacturers are increasingly prioritizing formulations that maintain consistent medication concentrations and reduce fluctuating clinical responses. Strong physician familiarity, established treatment guidelines, and extensive pharmacy availability support sustained demand for decarboxylase inhibitor combinations.\

• Dopamine Agonists: Dopamine agonists account for an estimated 21% of the Parkinson disease drug market, supported by established utilization in neurological treatment. These medications stimulate dopamine receptors and can be prescribed independently or alongside levodopa depending on patient characteristics. Pramipexole, ropinirole, rotigotine, and apomorphine are important therapies within this category. Selective D1/D5 receptor agonists represent an additional technological development within dopamine-targeted treatment. Pharmaceutical innovation increasingly focuses on improved receptor selectivity, convenient medication administration, and management of motor fluctuations. However, adverse effects such as hallucinations, daytime sleepiness, and impulse control disturbances require clinical supervision. Growing availability of differentiated formulations supports continuing competition among neurological drug manufacturers.

• Monoamine Oxidase Type B (MAO-B) Inhibitor: Monoamine oxidase type B inhibitors contribute an estimated 12% of the Parkinson disease drug market. These medications reduce enzymatic dopamine breakdown, helping maintain available dopamine activity within the brain. Rasagiline, selegiline, and safinamide represent established treatments within this therapeutic category. Neurologists may prescribe these medications during earlier disease stages or introduce them as adjunctive therapies when levodopa treatment requires additional support. Convenient oral administration and established clinical familiarity contribute to pharmaceutical adoption. Manufacturers continue evaluating combination strategies designed to improve movement control and reduce symptom fluctuations. Medication interactions, contraindications, and differences in patient responsiveness remain important considerations influencing prescription decisions and market performance.

• Catechol-O-Methyltransferase (COMT) Inhibitors: Catechol-O-methyltransferase inhibitors represent an estimated 8% of the Parkinson disease drug market, primarily supporting adjunctive treatment alongside levodopa. These medications inhibit an enzyme involved in levodopa metabolism, extending therapeutic availability and supporting movement symptom management. Entacapone, opicapone, and tolcapone are established treatments associated with this mechanism. Neurologists frequently consider COMT inhibitors when patients experience wearing-off symptoms between levodopa administrations. Pharmaceutical manufacturers are developing treatment approaches emphasizing convenient administration and compatibility with existing medication regimens. Clinical utilization depends on patient tolerability, reimbursement policies, and physician prescribing preferences. Adverse reactions and specific safety monitoring requirements influence treatment selection across neurological healthcare settings.

• Others: The others category holds an estimated 10% share of the Parkinson disease drug market, incorporating medications targeting additional motor and nonmotor symptoms. This segment includes amantadine, anticholinergic treatments, adenosine A2A receptor antagonists, and selected medications addressing Parkinson disease psychosis. Pimavanserin acts through serotonin receptor pathways rather than conventional dopamine replacement mechanisms. Adenosine A2A receptor antagonism represents another therapeutic approach for managing movement-related complications. Pharmaceutical companies are investigating novel mechanisms addressing dyskinesia, hallucinations, cognitive impairment, and additional neurological symptoms. Growing recognition of comprehensive symptom management supports demand for specialized medications. However, clinical effectiveness, patient tolerability, and treatment accessibility remain important factors affecting adoption.

By Application

Based on Application the global market can be categorized in to Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy.

• Hospital Pharmacy: Hospital pharmacies account for an estimated 24% of the Parkinson disease drug market, supported by specialized neurological treatment and complex pharmaceutical management. Hospitals play an important role in medication optimization, acute neurological assessment, and advanced treatment administration. Patients requiring continuous infusion therapies or management of severe movement complications frequently depend on hospital-based pharmaceutical services. Hospital pharmacists collaborate with neurologists to assess medication interactions, adjust treatment schedules, and improve treatment safety. Increasing availability of specialized neurological care supports hospital pharmacy demand. Advanced treatment technologies also require medication education, clinical monitoring, and coordinated healthcare services. These requirements strengthen the position of hospital pharmacies within neurological pharmaceutical distribution.

• Retail Pharmacy: Retail pharmacies represent an estimated 59% of the Parkinson disease drug market, establishing this segment as the largest pharmaceutical distribution channel. Parkinson disease typically requires continuous outpatient medication, generating recurring prescription dispensing and long-term pharmacist engagement. Retail pharmacies supply carbidopa-levodopa combinations, dopamine agonists, MAO-B inhibitors, and additional neurological treatments. Extensive community pharmacy networks support medication accessibility and prescription continuity. Pharmacists provide adherence counseling, refill coordination, and medication interaction guidance. Patients managing mobility limitations benefit from convenient prescription renewals and medication delivery services. Established outpatient treatment practices and extensive pharmaceutical distribution infrastructure continue supporting retail pharmacy leadership in the Parkinson disease drug market.

• Online Pharmacy: Online pharmacies hold an estimated 17% share of the Parkinson disease drug market, reflecting increasing adoption of digital pharmaceutical distribution. Patients requiring long-term neurological treatment may benefit from electronic prescriptions, automatic medication refills, and home delivery services. Digital pharmacy platforms offer convenient access for individuals experiencing mobility restrictions or transportation challenges. Integration with telemedicine consultations and electronic health records supports improved medication coordination. Pharmaceutical distributors are increasingly investing in secure prescription verification, reliable delivery networks, and digital medication management services. However, regulatory requirements, counterfeit medicine concerns, and prescription authentication remain operational challenges. Increasing digital healthcare adoption supports opportunities for online pharmacy expansion.

Parkinson Disease Drug Market Regional Outlook

• North America

North America holds an estimated 38% share of the Parkinson disease drug market, supported by advanced healthcare infrastructure, extensive neurological research capabilities, and established pharmaceutical distribution networks. Approximately 1.1 million individuals in the United States live with Parkinson disease, creating substantial requirements for neurological medications and specialist medical care. Regional pharmaceutical demand is influenced by routine prescriptions, advanced treatment technologies, and access to specialized movement disorder centers. The United States contributes significantly to regional clinical research and commercialization of innovative neurological therapies. Canada also supports pharmaceutical demand through established healthcare services and specialist treatment networks. Manufacturers are increasingly introducing extended-release formulations, targeted dopamine therapies, and infusion-based treatment systems to improve medication effectiveness.

The North American Parkinson disease drug market benefits from approximately 90,000 annual Parkinson disease diagnoses in the United States, supporting continuing demand for pharmaceutical treatment. Hospital pharmacies provide specialized medication administration for patients experiencing advanced motor complications, while retail pharmacies support long-term outpatient treatment. Growing adoption of continuous subcutaneous infusion technologies strengthens specialized pharmaceutical distribution. Clinical research institutions and biotechnology companies are investigating disease-modifying treatments and novel drug mechanisms. However, medication affordability, reimbursement restrictions, and differences in specialist access remain important challenges. Pharmaceutical manufacturers are responding through patient assistance programs, neurological education initiatives, and clinical partnerships designed to improve treatment availability and medication adherence.

• Europe

Europe represents an estimated 27% of the Parkinson disease drug market, supported by established pharmaceutical manufacturing, aging demographics, and comprehensive neurological healthcare services. More than 1 million individuals are estimated to live with Parkinson disease across the European Union, creating substantial demand for established and advanced therapeutic medications. Germany, France, Italy, Spain, and the United Kingdom contribute significantly to regional neurological pharmaceutical activity. Healthcare systems throughout Europe emphasize chronic disease management, specialist neurological consultations, and access to prescribed medications. Pharmaceutical companies are expanding development of extended-release carbidopa-levodopa formulations and advanced dopamine-targeted therapies. Increasing research collaboration between academic institutions and biotechnology manufacturers supports development of differentiated treatment options.

European Parkinson disease drug market growth is also supported by clinical demand for convenient formulations and improved motor fluctuation management. Research has indicated that more than 80% of Parkinson disease patients may experience motor fluctuations during disease progression, highlighting an important treatment requirement. Neurologists increasingly evaluate adjunctive therapies and advanced formulations to maintain symptom control. Pharmaceutical reimbursement assessments play an important role in determining access to innovative treatments. Hospital pharmacies contribute to specialist therapy administration, while community pharmacies remain essential for routine prescription supply. Uneven access to neurologists and differences in national reimbursement policies continue influencing pharmaceutical utilization across European healthcare markets.

• Asia Pacific

Asia Pacific accounts for an estimated 25% of the Parkinson disease drug market, supported by demographic aging, expanding healthcare infrastructure, and increasing neurological disease recognition. Countries including China, Japan, India, South Korea, and Australia contribute to regional demand for neurological medications. Parkinson disease affects more than 10 million individuals worldwide, and densely populated Asian healthcare markets represent an important component of the global treatment population. Japan maintains established neurological research capabilities and specialist pharmaceutical services. China is expanding access to hospital-based neurological diagnosis and chronic disease treatment. India presents opportunities through increasing availability of affordable generic medicines, specialist clinics, and pharmaceutical manufacturing capabilities.

The Asia Pacific Parkinson disease drug market benefits from increasing investment in pharmaceutical research and neurological healthcare delivery. An estimated 4% of individuals with Parkinson disease receive a diagnosis before age 50, highlighting the importance of treatment accessibility across different demographic groups. Pharmaceutical manufacturers are developing affordable levodopa combinations, dopamine agonists, and advanced neurological formulations for regional healthcare systems. Improving hospital networks and expanding specialist training support medication utilization. However, differences in healthcare infrastructure between metropolitan and rural communities remain significant. Pharmaceutical distribution partnerships, telemedicine services, and local manufacturing capabilities offer opportunities to improve long-term treatment access across emerging Asian markets.

• Middle East & Africa

The Middle East & Africa represents an estimated 5% of the Parkinson disease drug market, reflecting developing neurological treatment infrastructure and increasing pharmaceutical accessibility. Healthcare systems in Saudi Arabia, the United Arab Emirates, South Africa, and Egypt contribute to regional demand. Parkinson disease is recognized as the second most common neurodegenerative disorder globally, emphasizing the importance of improving neurological treatment capacity across developing healthcare regions. Investment in specialized hospitals, pharmaceutical distribution facilities, and neurological training supports regional treatment development. Middle Eastern countries with established medical infrastructure are increasingly introducing advanced pharmaceutical therapies. Hospital pharmacies remain particularly important for patients requiring specialist neurological assessment and complex medication management.

The Middle East & Africa Parkinson disease drug market faces challenges associated with medication affordability and limited access to specialist neurological care. More than 10 million individuals worldwide live with Parkinson disease, demonstrating the importance of expanding effective treatment access beyond established pharmaceutical markets. Public healthcare modernization and private hospital investment are creating opportunities for pharmaceutical manufacturers and regional distributors. Generic levodopa formulations remain important because they provide accessible treatment options for patients requiring continuous medication. Pharmaceutical manufacturers can expand regional operations through distribution partnerships, clinical education, and improved supply reliability. Increasing neurological awareness and better diagnostic services may support earlier treatment initiation and more consistent pharmaceutical utilization.

• Rest of the World

The Rest of the World represents an estimated 5% of the Parkinson disease drug market, encompassing Latin American markets and additional territories outside the principal regional classifications. Brazil, Mexico, Argentina, and Chile contribute to neurological pharmaceutical demand through expanding healthcare services and established urban hospital networks. Parkinson disease is the second most common progressive neurodegenerative disorder, highlighting the clinical importance of accessible dopaminergic medications. Regional treatment demand is influenced by availability of generic pharmaceutical products, specialist neurological services, and government-supported healthcare programs. Retail pharmacies play an important role in routine prescription distribution, while specialist hospitals provide advanced neurological evaluation and treatment optimization.

The Rest of the World Parkinson disease drug market presents opportunities for pharmaceutical distribution expansion and improvements in neurological treatment access. Approximately 4% of patients with Parkinson disease receive a diagnosis before age 50, emphasizing the importance of effective treatment options throughout adulthood. Pharmaceutical manufacturers are increasingly exploring regional partnerships to improve medication supply and affordability. Digital health platforms may support specialist consultations and prescription coordination for patients located away from major healthcare centers. However, reimbursement limitations, inconsistent pharmaceutical availability, and unequal healthcare infrastructure constrain adoption of advanced treatments. Local manufacturing partnerships and improved neurological awareness may strengthen long-term pharmaceutical market development.

KEY INDUSTRY PLAYERS

The Parkinson disease drug market features multinational pharmaceutical companies, specialized neuroscience developers, generic medicine manufacturers, and advanced therapeutic technology providers. AbbVie is strengthening its neurological treatment portfolio through continuous infusion technologies and selective D1/D5 receptor agonists. Acadia Pharmaceuticals maintains an established position in Parkinson disease psychosis treatment through its specialized neurological medicine portfolio. Other important participants include UCB, Orion Pharma, Novartis, Teva Pharmaceutical Industries, and Lundbeck. Competition increasingly emphasizes regulatory approvals, formulation differentiation, clinical effectiveness, and treatment convenience. Pharmaceutical developers are also pursuing targeted research partnerships, advanced medication delivery systems, and neurological drug development strategies to address persistent treatment limitations.

List of Top Parkinson Disease Drug Companies

• UCB S.A.
• Merck & Co., Inc.
• GlaxoSmithKline plc
• Medtronic plc
• AbbVie Inc.
• Pfizer Inc.
• Orion Pharma
• Hoffmann-La Roche Ltd.
• Lundbeck A/S
• Impax Laboratories, Inc.
• Sanofi S.A.
• Vertical Pharmaceuticals, LLC
• Novartis AG
• F. Hoffmann-La Roche AG
• Teva Pharmaceutical Industries Ltd.
• ACADIA Pharmaceuticals Inc.
• C.H. Boehringer Sohn AG & Co. KG

Investment Analysis and Opportunities

Investment opportunities in the Parkinson disease drug market are increasing through development of advanced pharmaceutical formulations, targeted neurological medicines, and innovative drug delivery systems. More than 10 million individuals worldwide are living with Parkinson disease, establishing substantial long-term demand for effective neurological therapies. Pharmaceutical investors are increasingly evaluating companies developing continuous subcutaneous infusion technologies, extended-release levodopa formulations, and targeted dopamine receptor medicines. Selective D1/D5 receptor agonists represent a differentiated therapeutic mechanism attracting attention from specialized neuroscience developers. Investment activity also focuses on treatment adherence technologies, digital medication management platforms, and integrated pharmaceutical distribution services. Partnerships between biotechnology manufacturers and established pharmaceutical companies can support clinical development, regulatory submissions, and commercialization of advanced treatment products.

Additional Parkinson disease drug market opportunities are emerging through research into disease-modifying therapies, neuroprotective compounds, and personalized neurological treatments. Approximately 80% of patients may experience sleep disturbances during disease progression, highlighting unmet demand for comprehensive symptom management. Pharmaceutical manufacturers are exploring medications addressing dyskinesia, hallucinations, cognitive symptoms, and declining movement control. Advanced clinical research programs frequently include 3 major trial phases, creating opportunities for specialized development organizations and research institutions. Emerging healthcare markets also offer opportunities for affordable generic formulations, improved prescription distribution, and specialist neurological services. However, lengthy development programs, uncertain clinical outcomes, reimbursement negotiations, and manufacturing complexity influence investment decisions. Companies demonstrating meaningful patient benefits and reliable pharmaceutical accessibility may achieve stronger competitive positioning.

New Product Development

New product development in the Parkinson disease drug market increasingly emphasizes improved medication effectiveness, convenient administration, and targeted neurological mechanisms. Selective D1/D5 receptor agonists introduce differentiated approaches to dopamine stimulation and motor symptom management. Continuous subcutaneous infusion devices enable consistent medication administration for selected patients experiencing advanced Parkinson disease motor fluctuations. Extended-release carbidopa-levodopa formulations are designed to maintain therapeutic drug availability and improve daily symptom control. Clinical investigations involving patients switching to Crexont from Rytary demonstrated 3.07 additional daily hours of good on time in an interim study subgroup. Pharmaceutical innovation also targets psychosis, dyskinesia, and disease-modifying mechanisms.

Recent Developments

•  February 2025: Supernus Pharmaceuticals Supernus secured regulatory approval for Onapgo, a continuous subcutaneous apomorphine infusion system designed to manage motor fluctuations in advanced Parkinson disease and improve treatment consistency through wearable medication delivery technology.
• April 2026:  Amneal Pharmaceuticals Amneal announced positive interim clinical findings for Crexont, demonstrating 3.07 additional hours of daily good on time among patients transitioning from Rytary, supporting extended-release carbidopa-levodopa treatment development for motor fluctuation management.

Report Coverage

The Parkinson disease drug market report provides comprehensive analysis of 5 therapeutic categories, including decarboxylase inhibitors, dopamine agonists, MAO-B inhibitors, COMT inhibitors, and other neurological medications. The study also evaluates 3 major pharmaceutical distribution channels comprising hospital pharmacies, retail pharmacies, and online pharmacies. Regional coverage examines North America, Europe, Asia Pacific, Middle East & Africa, and Rest of the World. Competitive assessment includes pharmaceutical manufacturers, neurological drug developers, and specialized treatment providers. The report examines disease prevalence, treatment innovation, pharmaceutical accessibility, clinical research activity, regulatory developments.